Skip to main content

Table 1 SUVmax values and LV function characteristics at different time points in Metformin group (n = 6) and Control group (n = 6)

From: Evaluating the cardioprotective effect of metformin on myocardial ischemia–reperfusion injury using dynamic 18F-FDG micro-PET/CT imaging

Indicators

Groups

Day 1st

Day 7th

Day 14th

Day 30th

Ischemia center (mm3)

Met

2.02 ± 0.40

1.80 ± 1.16

2.31 ± 0.84

1.91 ± 0.18

Con

3.75 ± 2.33

3.20 ± 0.42

2.33 ± 0.17

3.22 ± 0.21

Peri-ischemia (mm3)

Met

2.61 ± 0.33

2.51 ± 1.34

2.70 ± 0.68

2.15 ± 0.94

Con

4.32 ± 1.33

3.91 ± 0.98

2.85 ± 0.38

4.25 ± 0.98

Remote Area (mm3)

Met

2.41 ± 0.80

2.14 ± 0.52

2.82 ± 0.88

2.33 ± 0.44

Con

4.15 ± 0.99

3.60 ± 0.17

2.80 ± 0.14

4.85 ± 0.41

Center/Remote ratio

Met

0.71 ± 0.16

0.73 ± 0.05

0.78 ± 0.13

0.88 ± 0.06#

Con

0.72 ± 0.18*

0.77 ± 0.14*

0.76 ± 0.17*

0.72 ± 0.09#*

ESV (mm3)

Met

88.10 ± 15.58

60.10 ± 34.31

92.66 ± 36.50

68.00 ± 8.48

Con

80.50 ± 2.21

68.20 ± 24.55

99.12 ± 30.40

75.41 ± 6.23

EDV (mm3)

Met

254.20 ± 70.19

291.61 ± 65.58

329.67 ± 74.60

358.21 ± 22.62#

Con

217.12 ± 19.79*

270.92 ± 26.61*

349.67 ± 46.66*

407.53 ± 29.91#*

LVEF (%)

Met

70.80 ± 2.24

79.59 ± 3.42

76.22 ± 3.12

81.01 ± 1.42

Con

67.85 ± 2.28

78.41 ± 2.45

73.09 ± 2.99

83.58 ± 1.12

  1. Data are presented as mean ± SD or percentage (%) of subjects
  2. ESV end-systolic volume, EDV end-diastolic volume, LVEF left ventricular ejection fraction
  3. #Comparison between Met group and Control group, p < 0.05
  4. *Correlation analysis between Center / Remote ratio and EDV, p < 0.05